VETCE ON DEMAND: LESS FEAR, MORE HOPE: HOW RESEARCH IS DRIVING NEW STRATEGIES IN HEMANGIOSARCOMA TREATMENT AND PREVENTION

Continuing Education Credits
Course meets the requirements for 1 RACE hours of continuing education credit for veterinary technicians and veterinarians in jurisdictions which recognize AAVSB's RACE approval. However, participants should be aware that some boards have limitations on the number of hours accepted in certain categories and/or restrictions on certain methods of delivery. RACE Subject Category: Medical; Delivery Method: Non-interactive Distance; Program Number 1330566.

Continuing Education Credits

Course meets the requirements for 1 RACE hours of continuing education credit for veterinary technicians and veterinarians in jurisdictions which recognize AAVSB's RACE approval. However, participants should be aware that some boards have limitations on the number of hours accepted in certain categories and/or restrictions on certain methods of delivery.

RACE Subject Category: Medical; Delivery Method: Non-interactive Distance; Program Number 1330566.

Content Presenter
Antonella Borgatti, DVM, MS, DACVIM (Oncology), DECVIM-CA

Course Focus and Learning Objectives
VetCE on Demand: Less Fear, More Hope - How Research is Driving New Strategies in Hemangiosarcoma Treatment and Prevention utilizes the archive of a live presentation under the same name. Hemangiosarcoma remains one of the most challenging and devastating diseases in veterinary medicine. Its heterogeneity and aggressive nature have made meaningful therapeutic progress frustratingly slow. This course introduces a forward-thinking approach that combines cutting-edge targeted therapies with rationally designed preventative strategies, offering hope for better outcomes for patients, clients, and veterinary teams alike. After completion of this course, the student should be able to: describe the mechanism of action and therapeutic potential of eBAT, a bispecific targeted angiotoxin discuss the rationale, design, and preliminary outcomes of the PRO-DOX clinical trial investigating propranolol as an adjunct to doxorubicin chemotherapy outline emerging knowledge of targeted therapies and preventative strategies to clinical discussions with clients

Course Focus and Learning Objectives

VetCE on Demand: Less Fear, More Hope - How Research is Driving New Strategies in Hemangiosarcoma Treatment and Prevention utilizes the archive of a live presentation under the same name.

Hemangiosarcoma remains one of the most challenging and devastating diseases in veterinary medicine. Its heterogeneity and aggressive nature have made meaningful therapeutic progress frustratingly slow. This course introduces a forward-thinking approach that combines cutting-edge targeted therapies with rationally designed preventative strategies, offering hope for better outcomes for patients, clients, and veterinary teams alike.

After completion of this course, the student should be able to:

describe the mechanism of action and therapeutic potential of eBAT, a bispecific targeted angiotoxin
discuss the rationale, design, and preliminary outcomes of the PRO-DOX clinical trial investigating propranolol as an adjunct to doxorubicin chemotherapy
outline emerging knowledge of targeted therapies and preventative strategies to clinical discussions with clients

Open Enrollment with Immediate Access and Individual Scheduling
This is an open-enrollment course. Participants may enroll at any time. Upon submission of enrollment, the participant is immediately added to the course. The course welcome email provides login and other important information. This is an asynchronous course, meaning it does not contain real-time components. Participants do not need to be logged into the course at specific times to attend lectures or view presentations. Participants do not need to complete the course in one sitting. Completion Deadline: Participants have 30 days from the date of enrollment to view the presentation, as often as desired, as well as submit the two completion requirements outlined below. If, after 30 days, the completion requirements have not been submitted, the participant will be graded out of the course as incomplete.

Open Enrollment with Immediate Access and Individual Scheduling

This is an open-enrollment course. Participants may enroll at any time. Upon submission of enrollment, the participant is immediately added to the course. The course welcome email provides login and other important information.

This is an asynchronous course, meaning it does not contain real-time components. Participants do not need to be logged into the course at specific times to attend lectures or view presentations. Participants do not need to complete the course in one sitting.

Completion Deadline:

Participants have 30 days from the date of enrollment to view the presentation, as often as desired, as well as submit the two completion requirements outlined below. If, after 30 days, the completion requirements have not been submitted, the participant will be graded out of the course as incomplete.

Completion Requirements
The completion requirements for this course are: complete the quiz with a score of 80% or better - multiple attempts are permitted submit the course survey Upon submission of the final completion requirement, the participant will automatically be marked as completed and the course completion email will be sent out. The participant will have immediate access to the certificate.

Course Fee
Price: $15.00 USD Practices may enroll individual team members. To learn how to assign a specific team member to a course, please visit the Assigning Students page. Please use this link to view the Withdrawal Policy for this course.

VETCE ON DEMAND: LESS FEAR, MORE HOPE: HOW RESEARCH IS DRIVING NEW STRATEGIES IN HEMANGIOSARCOMA TREATMENT AND PREVENTION

Follow Us & Share